IL-15 (mutant) (human):Fc (mouse) (rec.) (Biotin)

Chimerigen
Product Code: CHI-HF-21115MBI
Product Group: Recombinant Proteins
Supplier: Chimerigen

CodeSizePrice
CHI-HF-21115MBI-11 Vial£455.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Hamster
Regulatory Status: RUO
Target Species: Human
Shipping:
BI
Storage:
-20°C

Further Information

Alternate Names/Synonyms:
Interleukin-15
Biological Activity:
This mutant IL-15/Fc fusion protein specifically binds to the IL-15R, competitively inhibits IL-15-triggered cell proliferation, promotes transplant tolerance, does not activate the STAT-signaling pathway, and exerts a prolonged circulating half-life caused by the modified Fc domain.
EClass:
32160000
Endotoxin:
<0.06EU/µg protein (LAL test; Lonza).
Form (Short):
solid
Formulation:
Lyophilized. In PBS and 0.09% sodium azide.
Handling Advice:
Avoid freeze/thaw cycles.Centrifuge lyophilized vial before opening and reconstitution.
Labels - Conjugates:
Biotin
Long Description:
Protein. The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of mouse IgG2a. Source: CHO cells. Endotoxin content: <0.06EU/µg protein (LAL test; Lonza). Lyophilized. In PBS and 0.09% sodium azide. Purity: >98% (SDS-PAGE). Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ralpha, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines. Application: Useful for immunofluorescent staining and flow cytometric analysis to identify and enumerate IL-15Ralpha expressing cells within mixed cell populations.
NCBI, Uniprot Number:
NP_751914.1
Package Type:
Plastic Vial
Product Description:
Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ralpha, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines. Application: Useful for immunofluorescent staining and flow cytometric analysis to identify and enumerate IL-15Ralpha expressing cells within mixed cell populations.
Purity:
>98% (SDS-PAGE)
Sequence:
The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of mouse IgG2a.
Source / Host:
CHO cells
TAGs:
Fc
Transportation:
Non-hazardous
UNSPSC Category:
Interleukins
UNSPSC Number:
41116127
Use & Stability:
Stable for at least 6 months after receipt when stored at +4°C.

References

Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity: Y.S. Kim, et al.; J. Immunol. 160, 5742 (1998) | An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection: S. Ferrari-Lacraz, et al.; J. Immunol. 167, 3478 (2001) | Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance: X.X. Zheng, et al.; Immunity 19, 503 (2003) | Limiting gammac expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors: C.M. Smyth, et al.; Blood 110, 91 (2007)